Theratechnologies Confirms Bioequivalence Of New Tesamorelin Formulation

Jul 07, 2020
PDF Version
Supporting Materials:

sBLA expected to be filed in early 2022

 Seven-day multidose vial and room temperature stability allow for the potential use of tesamorelin with a multidose pen injector

 Montreal, Canada – July 7, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that it has successfully completed a bioequivalence study evaluating a new formulation of tesamorelin compared to the original formulation approved by the FDA (F1).